Compare Oscar Health Inc (OSCR) vs Unilever plc (UL) Price & Performance

Oscar Health (OSCR) trades at $32.91, up 1.76% with strong technical momentum and bullish moving average signals. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B in 2026, with profitability turning positive at $551M net income. Recent earnings beats and raised guidance have driven positive sentiment, though the stock faces challenges from rising medical costs and competitive pressures in the ACA market.

The outlook remains constructive with analyst consensus at $34.00 and strong institutional interest, though investors should monitor execution risks and medical cost trends. The combination of market share gains, margin expansion potential, and bullish technical setup supports further upside if the company can maintain its growth trajectory.

Unilever (UL) trades at $60.98, up 0.3% on the day, amid a bearish technical signal and mixed earnings performance. The company reported Q2 2026 EPS of $1.83, narrowly missing the $1.84 estimate, continuing a trend of recent misses. Financially, UL maintains strong profitability with an 18.32% net income margin and 54.56% ROE, though revenue declined to $50.5B in 2025. Analyst sentiment is divided with a Hold consensus, while news highlights strategic shifts including the planned food business merger with McCormick.

The outlook balances high profitability and emerging market exposure against execution risks from portfolio restructuring and recent earnings misses. The stock's valuation at a P/E of 21.32 appears reasonable relative to historical margins, but investor caution is warranted given the bearish technical trend and regulatory scrutiny of the McCormick deal. Upside potential hinges on successful integration and volume growth sustainability.